KR950011408A - 사이클릭 아민 유도체 - Google Patents

사이클릭 아민 유도체 Download PDF

Info

Publication number
KR950011408A
KR950011408A KR1019940026700A KR19940026700A KR950011408A KR 950011408 A KR950011408 A KR 950011408A KR 1019940026700 A KR1019940026700 A KR 1019940026700A KR 19940026700 A KR19940026700 A KR 19940026700A KR 950011408 A KR950011408 A KR 950011408A
Authority
KR
South Korea
Prior art keywords
formula
compound
carbon atoms
methylsulfonamidophenylethyl
physiologically acceptable
Prior art date
Application number
KR1019940026700A
Other languages
English (en)
Inventor
바움가르트 만프레드
루에스 잉게
밍크 클라우스-옷토
Original Assignee
위르겐 호이만, 라인하르트 슈틀러
메르크 파텐트 게젤샤프트 미트 베쉬랭크터 하프퉁
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 위르겐 호이만, 라인하르트 슈틀러, 메르크 파텐트 게젤샤프트 미트 베쉬랭크터 하프퉁 filed Critical 위르겐 호이만, 라인하르트 슈틀러
Publication of KR950011408A publication Critical patent/KR950011408A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/42—Oxygen atoms attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/08—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

하기 일반식(Ⅰ)의 사이클릭 아민 유도체 및 그의 생리학적으로 허용가능한 염은 항부정맥 효과를 나타낸다 :
상기식에서, Ar 및 Ar'는 각각 서로 독립적으로, 비치한되거나 또는 NO2, NH2, Hal, CF3, A, NHSo2A 또는 NHAc에 의해 한번 또는 두번 치환된 페닐이고, X 및 Y는 각각 서로 독립적으로, 0 또는 결합이고, m은 0 또는 1이고, n은 0, 1 또는 2이고, p은 0,1,2 또는 3이고, q은 2 또는 3이고, A는 탄소원자수 1 내지 6개의 알킬이고, Hal은 F, Cl, Br 또는 1이고, Ac는 탄소원자수 1 내지 8개의 알카노일, 탄소원자수 8 내지 10개의 아르알카노일 또는 탄소원자수 7 내지 11개의 아로일이다.

Description

사이클릭 아민 유도체
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (8)

  1. 하기 일반식(Ⅰ)의 사이클릭 아민 유도체 및 이들의 생리학적으로 허용가능한 염 :
    상기식에서, Ar 및 Ar'는 각각 서로 독립적으로, 비치한되거나 또는 NO2, NH2, Hal, CF3, A, NHSo2A 또는 NHAc에 의해 한번 또는 두번 치환된 페닐이고, X 및 Y는 각각 서로 독립적으로, 0 또는 결합이고, m은 0 또는 1이고, n은 0, 1 또는 2이고, p은 0,1,2 또는 3이고, q은 2 또는 3이고, A는 탄소원자수 1 내지 6개의 알킬이고, Hal은 F, Cl, Br 또는 1이고, Ac는 탄소원자수 1 내지 8개의 알카노일, 탄소원자수 8 내지 10개의 아르알카노일 또는 탄소원자수 7 내지 11개의 아로일이다.
  2. 제1항에 따르는 일반식(Ⅰ)화합물의 거울상이성질체.
  3. (a) 1-(2-p-메틸설폰아미도페닐에틸)-3-(p-메틸설폰아미도페녹시)피페리딘; (b) 1-(2-p-메틸설폰아미도페닐에틸)-2-(p-메틸설폰아미도페녹시메틸)피롤리딘; (c) 1-(2-p-메틸설폰아미도페닐에틸)-3-(p-니트로페녹시)피롤리딘; (d) 1-(2-p-아세트아미도페닐에틸)-3-(p-아세트아미도페녹시)피롤리딘; (e) 1-(2-p-메틸설폰아미도페닐에틸)-3-(p-메틸설폰아미도페녹시)피롤리딘; (f) 1-(2-p-니트로페닐에틸)-2-(p-니트로페녹시메틸)피페리딘; (g) 1-(2-p-니트로페닐에틸)-3-(p-니트로페녹시헥사하이드로아제핀; (h) 1-(2-p-메틸설폰아미도페닐에틸)-2-(p-메틸설폰아미도페녹시메틸)피페리딘; (i) 1-(2-p-메틸설폰아미도페닐에틸)-3-(p-메틸설폰아미도페녹시헥사하이드로아제핀; (j) 1-(2-p-메틸설폰아미도페닐에틸)-4-(p-메틸설폰아미도페녹시)피페리딘; (k) 1-(2-p-메틸설폰아미도페닐에틸)-3-(p-메틸설폰아미도페녹시메틸)피페리딘.
  4. 하기 일반식(Ⅱ)의 화합물을 하기 일반식(Ⅲ)의 화합물과 반응시키거나, 또는 Y가 산소인 제1항에 따르는 하기 일반식(Ⅰ)의 화합물을 제조하기 위해, 하기 일반식(Ⅳ)의 화합물을 하기 일반식(Ⅴ)의 화합물과 반응시키거나, 또는 하기 일반식(Ⅴa)의 화합물을 하기 일반식(Ⅵ)의 화합물과 반응시키거나, 또는 일반식(Ⅰ)에 상응하지만, 하나 이상의 CH2대신에 하나 이상의 환원가능한 그룹을 갖는 화합물을 환원에 의해 일반식(Ⅰ)의 화합물로 전환시키고/시키거나, 일반식(Ⅰ)의 화합물중의 Ar 및 Ar'그룹 중 하나 또는 두개 모두를 각각 다른 라디칼 Ar 및 Ar'로 전환시키고/시키거나, 일반식(I)의 염기성 화합물을 산으로 처리하여 그의 생리학적으로 허용가능한 산 부가염증의 하나로 전환시킴을 특징으로 하는, 제1항에 따르는 일반식(Ⅰ)의 화합물의 제조 방법 :
    Ar-X-(CH2)q-L (Ⅲ)
    Ar'-Z (Va)
    상기식에서, Ar 및 Ar'는 각각 서로 독립적으로, 비치한되거나 또는 NO2, NH2, Hal, CF3, A, NHSo2A 또는 NHAc에 의해 한번 또는 두번 치환된 페닐이고, X 및 Y는 각각 서로 독립적으로, 0 또는 결합이고, m은 0 또는 1이고, n은 0, 1 또는 2이고, p은 0,1,2 또는 3이고, q은 2 또는 3이고, A는 탄소원자수 1 내지 6개의 알킬이고, Hal은 F, Cl, Br 또는 1이고, Ac는 탄소원자수 1 내지 8개의 알카노일, 탄소원자수 8 내지 10개의 아르알카노일 또는 탄소원자수 7 내지 11개의 아로일이고, L은 OH, Cl, Br 또는 반응성, 작용성 변형 OH 그룹이고, Z는 OH 또는 염과 유사한 특성을 가진 그룹을 포함하는 반응성, 작용서 변형 OH 그룹이다.
  5. 적어도 하나의 고형, 액체 또는 반고체 비히클 또는 보조 물질과 함께 일반식(Ⅰ)의 화합물 및/또는 그의 생리학적으로 허용가능한 염중 하나를 적합한 투여 형태로 전환시킴을 특징으로 하는, 약학적 제제의 제조 방법.
  6. 일반식(Ⅰ)의 적어도 하나의 화합물 및/또는 그의 생리학적으로 허용가능한 염중 하나를 함유함을 특징으로 하는 약학적 제제.
  7. 약물을 제조하기 위한 제1항에 따른 일반식(Ⅰ)의 화합물 또는 그의 생리학적으로 허용가능한 염의 용도.
  8. 질병을 치료하기 위한 제1항에 따른 일반식(Ⅰ)의 화합물 또는 그의 생리학적으로 허용가능한 염의 용도.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019940026700A 1993-10-20 1994-10-19 사이클릭 아민 유도체 KR950011408A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4335718A DE4335718A1 (de) 1993-10-20 1993-10-20 Cyclische Aminderivate
DEP4335718.0 1993-10-20

Publications (1)

Publication Number Publication Date
KR950011408A true KR950011408A (ko) 1995-05-15

Family

ID=6500552

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940026700A KR950011408A (ko) 1993-10-20 1994-10-19 사이클릭 아민 유도체

Country Status (15)

Country Link
EP (1) EP0649838A1 (ko)
JP (1) JPH07188162A (ko)
KR (1) KR950011408A (ko)
CN (1) CN1107469A (ko)
AU (1) AU7588394A (ko)
CA (1) CA2118375A1 (ko)
CZ (1) CZ257794A3 (ko)
DE (1) DE4335718A1 (ko)
HU (1) HUT72294A (ko)
NO (1) NO943961L (ko)
PL (1) PL305487A1 (ko)
RU (1) RU94038254A (ko)
SK (1) SK125994A3 (ko)
TW (1) TW275062B (ko)
ZA (1) ZA948211B (ko)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9610741B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
ZA9610736B (en) * 1995-12-22 1997-06-27 Warner Lambert Co 2-Substituted piperidine analogs and their use as subtypeselective nmda receptor antagonists
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
ZA9610745B (en) * 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
GB9725541D0 (en) * 1997-12-02 1998-02-04 Pharmacia & Upjohn Spa Amino-benzothiazole derivatives
CA2422055A1 (en) * 2000-09-11 2002-03-21 Sepracor, Inc. Ligands for monoamine receptors and transporters, and methods of use thereof (neurotransmission)
DE10135043A1 (de) * 2001-07-11 2003-01-30 Bayer Cropscience Gmbh Substituierte 3-Heteroaryl(amino- oder oxy)-pyrrolidin-2-one, Verfahren zu deren Herstellung und Verwendung als Herbizide oder als Pflanzenwachstumsregulatoren
WO2003049736A1 (en) 2001-12-11 2003-06-19 Sepracor, Inc. 4-substituted piperidines, and methods of use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1219865A (en) * 1982-05-14 1987-03-31 Leo Alig Aziridine phenethanolamine derivatives
DK623586A (da) * 1985-12-27 1987-06-28 Eisai Co Ltd Piperidinderivater eller salte deraf og farmaceutiske kompositioner indeholdende forbindelserne
GB8720910D0 (en) * 1987-09-05 1987-10-14 Pfizer Ltd Antiarrhythmic agents
WO1990006303A1 (en) * 1988-12-02 1990-06-14 Pfizer Inc. Arylpiperidine derivatives
GB8929331D0 (en) * 1989-12-29 1990-02-28 Shell Int Research Piperidine derivatives
GB9100505D0 (en) * 1991-01-10 1991-02-20 Shell Int Research Piperidine derivatives
FR2681319B1 (fr) * 1991-09-12 1995-02-17 Synthelabo Derives de 1-(phenoxyalkyl)piperidine, leur preparation et leur application en therapeutique.
US5202346A (en) * 1992-02-25 1993-04-13 American Home Products Corporation Piperidinyl and piperazinyl derivatives

Also Published As

Publication number Publication date
RU94038254A (ru) 1996-09-10
NO943961D0 (no) 1994-10-19
EP0649838A1 (de) 1995-04-26
HU9403010D0 (en) 1994-12-28
AU7588394A (en) 1995-05-11
JPH07188162A (ja) 1995-07-25
HUT72294A (en) 1996-04-29
ZA948211B (en) 1995-06-12
CZ257794A3 (en) 1995-11-15
CA2118375A1 (en) 1995-04-21
PL305487A1 (en) 1995-05-02
DE4335718A1 (de) 1995-04-27
TW275062B (ko) 1996-05-01
SK125994A3 (en) 1995-05-10
CN1107469A (zh) 1995-08-30
NO943961L (no) 1995-04-21

Similar Documents

Publication Publication Date Title
KR970704702A (ko) 치환된 피리미딘 화합물 및 그의 용도(Substituted Pyrimidine Compounds and Their Use)
EP1036794A4 (en) 2-ARYL-8-OXODIHYDROPURIN DERIVATIVES, THEIR PRODUCTION, THEIR USE AS MEDICINE COMPONENTS AND THEIR INTERMEDIATES
HUT55228A (en) Process for producing pharmaceutical composition comprising imidazole derivatives with antinociceptive effect
KR900006318A (ko) 피페리디닐 벤즈이미다졸
KR930023340A (ko) 아릴아세트아미드
KR960037675A (ko) 벤조니트릴 및 벤조플루오라이드
EP1153924A3 (en) Substituted 1,3-oxathiolanes with antiviral properties
ES2149537T3 (es) Resina intercambiadora de aniones no reticulados y composicion farmaceutica que contiene la misma.
KR890002060A (ko) 옥사졸리디논 화합물
KR950011408A (ko) 사이클릭 아민 유도체
DE3670081D1 (de) Imidazolderivate, verfahren zu deren herstellung, deren anwendung und pharmazeutische zusammenstellungen.
EP0369744A3 (en) Xanthine derivatives, process for their preparation and pharmaceutical compositions
BR9503536A (pt) Composto processo para sua preparação seu uso e composição farmacêutica
CA2191874A1 (en) Novel processes and intermediates for the preparation of piperazine derivatives
CA2252402A1 (en) Carbapenem antibacterial compounds, compositions containing such compounds and methods of treatment
ATE46511T1 (de) Neue 8-alkylthio-2-piperazino-pyrimido(5,4d>pyrimidine, ihre herstellung und diese verbindungen enthaltende arzneimittel.
NZ332545A (ko)
KR920002517A (ko) 칼모둘린 억제 특성을 갖는 벤즈히드릴 유도체 및 그의 제조방법
KR910021400A (ko) 옥사졸리디논
ATE215934T1 (de) Neue histidinderivate, verfahren zu ihrer herstellung und ihre verwendung als mittel gegen freie radikale
KR880011098A (ko) 4-페닐피페리딘 화합물, 이의 제조방법 및 용도
KR930000504A (ko) 2-피페리디닐 피리미딘-4-카르복시아미드 유도체의 제법 및 치료에의 이용
KR940005279A (ko) 아미딘을 함유하는 약제학적 조성물 및 아미딘
EP0149583A3 (fr) 3-Alkoxy-2(N-pyrrolidino)-N-pyridyl-N-furyl (ou thienyl)-methyl-propylamines, leur préparation et les compositions pharmaceutiques les contenant
KR950032160A (ko) 1-[2-1h-인덴-3-일)에틸]-4-(나프트-1- 일) 피페라진 유도체, 그의 제법 및 치료학적 이용

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid